EGFR and cancer: On the other hand, data from in vitro assays indicated that SPINK1 effects are mediated predominantly through EGFR, but the involvement of other RTKs yet remains possible, an issue raised by former studies29,58 which can alternatively explain the higher efficacy of SPINK1 mAb in antagonizing cancer progression than an EGFR-targeting antibody.